SCHEMBL5459967

SCHEMBL5459967

Cc1cnc(NC(=O)Nc2ccc(N3CCN(C(=O)O)CC3)cc2)s1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.59
KMT2A Q03164 6/20 0.59
MEN1 O00255 5/20 0.59
RAB9A P51151 4/20 0.59
SMN1; SMN2 Q16637 4/20 0.59
NFKB1 P19838 1/20 0.59
NFKB2 Q00653 1/20 0.59
RELA Q04206 1/20 0.59
AURKA O14965 1/20 0.56
KDR P35968 1/20 0.56
FLT3 P36888 1/20 0.56
OGA O60502 1/20 0.46
NPC1 O15118 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
PKM P14618 2/20 0.44
GAA P10253 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
CCNE1 P24864 2/20 0.44
CDK2 P24941 2/20 0.44
CDK5 Q00535 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5463529 0.85 KMT2A (0.62) MAPTKMT2AMEN1RAB9ASMN1; SMN2
SCHEMBL5453617 0.85 RAB9A (0.60) MAPTKMT2AMEN1RAB9ASMN1; SMN2
SCHEMBL5460991 0.82 RAB9A (0.59) MAPTKMT2AMEN1RAB9ASMN1; SMN2
SCHEMBL6285776 0.77 RAB9A (0.74) MAPTKMT2AMEN1RAB9ASMN1; SMN2
SCHEMBL6282915 0.75 RAB9A (0.74) MAPTKMT2AMEN1RAB9ASMN1; SMN2
SCHEMBL5459659 0.75 LMNA (0.48) MAPTKMT2AMEN1RAB9ALMNA
SCHEMBL5459850 0.75 RAB9A (0.64) MAPTKMT2AMEN1RAB9ASMN1; SMN2
SCHEMBL5460936 0.74 MAPT (0.68) MAPTKMT2AMEN1RAB9ANPC1
SCHEMBL5459930 0.74 NAMPT (0.56) MAPTKMT2AMEN1RAB9ASMN1; SMN2
SCHEMBL5460668 0.74 PANK3 (0.65) MAPTKMT2AMEN1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249620-A1 Urea Derivative SANKYO COMPANY, LIMITED (JP) 2007-10-25 US disclosed
EP-1764360-A1 UREA DERIVATIVE Sankyo Company, Limited (JP) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249620-A1 Urea Derivative UGP2, SLC14A1, DGAT1 MAPT 758/4885KMT2A 1350/4885MEN1 1828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.